IL17A and Alzheimer disease: While both treatments reduced these cytokines, EVs were more effective in lowering all Th1 (TNFα and IFN-γ), Th17 (IL-17) and Th22 (IL-22) cytokine levels involved in the inflammatory responses associated with AD.